Chimeric Protein IgE Blockade for Allergic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic disorders, such as atopic dermatitis in dogs, often result in suboptimal outcomes and are associated with severe side effects from prolonged use of corticosteroids and anti-inflammatory drugs, while existing anti-IgE therapies fail to effectively block IgE binding to mast cells and basophils, leading to incomplete relief from allergic reactions.
Innovation Solution
A chimeric protein comprising a single chain variable fragment (scFv) that binds to IgE at specific epitopes and an IgE high affinity receptor alpha chain, enhancing the affinity for IgE and blocking its binding to mast cells and basophils, thereby reducing free serum IgE levels and preventing allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If desensitization injections are used to treat allergic disorders, then some individuals show improvement, but most cases are not resolved and require additional medications
Solution Approach 1:
The patent modifies the mechanism of action by changing from traditional desensitization (which takes extended time) to a chimeric protein that directly blocks IgE binding to mast cells and basophils, achieving rapid and comprehensive effectiveness across most allergic disorder cases
2Reliability
If anti-inflammatory drugs and corticosteroids are used to treat allergic disorders, then clinical symptoms are suppressed, but severe side effects occur with prolonged use
Solution Approach 1:
The patent extracts and targets the root cause (IgE) directly through the chimeric protein that binds to and blocks IgE, eliminating the need for prolonged anti-inflammatory drug therapy and its associated side effects while maintaining effective symptom control
Solution Approach 2:
The chimeric protein acts as an intermediary that blocks the interaction between IgE and mast cells/basophils, preventing the allergic response pathway without requiring continuous anti-inflammatory medication, thus eliminating side effects while maintaining therapeutic effectiveness
3Quantity of substance
If existing anti-IgE therapies are used, then IgE binding is partially blocked, but they fail to effectively block IgE binding to mast cells and basophils
Solution Approach 1:
The patent creates a composite chimeric protein combining scFv (for high-affinity IgE binding) with the IgE high affinity receptor alpha chain (for blocking mast cell binding), achieving both reduction of free serum IgE and effective blocking of IgE binding to mast cells and basophils simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric protein effectively reduces circulating IgE levels and prevents allergic flare-ups in dogs, offering rapid relief and long-term control of clinical symptoms with fewer side effects compared to traditional treatments, including enhanced efficacy in IgE-resistant cases.
Implementation Method 1
a single chain variable fragment (scFv) that binds to IgE at an epitope corresponding to the amino acid sequence VDGQKATNIFPYTAPGTK
Implementation Method 2
enhancing the affinity for IgE and blocking its binding to mast cells and basophils
Data Source
AI summary
The present invention provides a chimeric protein comprising: a) a single chain variable fragment (scFv); b) a linker peptide; and c) an amino acid sequence comprising an IgE high affinity receptor alpha chain, and methods of use thereof.